Six years survival on imatinib with no disease progression after diagnosis of metastatic duodenal gastrointestinal stromal tumour: A case report
1 Department of General Surgery, George Eliot Hospital, College Street, Nuneaton, Warwickshire CV10 7DJ, UK
2 Department of General Surgery, Victoria Hospital, Whinney Heys Road, Blackpool, Lancashire FY3 8NR, UK
3 Institute of Clinical Sciences, Warwick Medical School, Coventry CV4 7AL, UK
Journal of Medical Case Reports 2008, 2:110 doi:10.1186/1752-1947-2-110Published: 18 April 2008
A duodenal Gastrointestinal Stromal Tumour (GIST) is a rare finding and until recently advanced disease had a poor prognosis. A PubMed search revealed no reports of more than five years survival of inoperable GIST on chemotherapy with WHO performance status zero.
A 68 year old female was diagnosed with unresectable GIST in the duodenum with metastasis to liver, pancreas and omentum in November 2001. She was commenced on imatinib mesylate (Glivec) chemotherapy. This case report was prepared from the medical records and radiology reports. She had good tolerance with stable disease. After six years her CT scan showed no disease progression and her WHO performance status was zero.
This report supports the view that imatinib is a safe and effective drug in controlling disease progression in advanced metastatic GIST and plays an important role in improving the patient's quality of life.